Suppr超能文献

镰状细胞性状与杰克逊心脏研究中的慢性肾脏病

, Sickle Cell Trait, and CKD in the Jackson Heart Study.

作者信息

Young Bessie A, Wilson James G, Reiner Alex, Kestenbaum Bryan, Franceschini Nora, Bansal Nisha, Correa Adolfo, Himmelfarb Jonathan, Katz Ronit

机构信息

UW Office of Healthcare Equity, Justice, Equity, Diversity, and Inclusion Center for Transformational Research (UW JEDI-CTR), University of Washington, Seattle WA.

Nephrology Section, Hospital and Specialty Medicine, Center for Innovation, Veterans Affairs Puget Sound Health Care System, Seattle WA.

出版信息

Kidney Med. 2021 Jul 15;3(6):962-973.e1. doi: 10.1016/j.xkme.2021.05.004. eCollection 2021 Nov-Dec.

Abstract

RATIONALE & OBJECTIVE: Apolipoprotein L1 () high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Americans with only 1 risk variant or whether the risk is modified by sickle cell trait.

STUDY DESIGN

The Jackson Heart Study is a community-based longitudinal cohort study.

SETTING & PARTICIPANTS: Self-reported African Americans in the Jackson Heart Study (n = 5,306).

EXPOSURES

G1 and G2 genotypes and sickle cell trait.

OUTCOMES

Incident CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m), albuminuria (urinary albumin-creatinine ratio ≥ 30 mg/g), continuous and rapid kidney function decline (≥30% decline), and incident ESKD.

ANALYTICAL APPROACH

Multivariable linear and logistic regression, and Cox proportional hazards models adjusted for age, sex, hypertension, diabetes, ancestry informative markers, and sickle cell trait.

RESULTS

Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 risk variants. Sickle cell trait was present in 8.5%. Compared with participants with zero risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57), continuous decline (β = -1.90; 95% CI, -3.35 to -0.45), and rapid kidney function decline (OR, 2.21; 95% CI, 1.22 to 4.00) after adjustment for sickle cell trait, with similar results after adjustment for ancestry informative markers. Having 1 risk variant was not associated with CKD outcomes and there was no interaction of with sickle cell trait.

LIMITATIONS

Single-site recruitment of African American individuals with and sickle cell trait.

CONCLUSIONS

The presence of 1 risk allele was not associated with increased risk for CKD outcomes, whereas 2 risk alleles were associated with incident albuminuria, CKD, ESKD, and rapid and continuous kidney function decline. Additional studies are needed to determine factors that might alter the risk for adverse kidney outcomes among individuals with high-risk genotypes.

摘要

原理与目的

载脂蛋白L1(APOL1)高风险变异与非裔美国人慢性肾脏病(CKD)风险增加相关。对于仅有1个APOL1风险变异的非裔美国人发生CKD和肾衰竭(终末期肾病[ESKD])的风险,以及该风险是否受镰状细胞性状影响,我们所知甚少。

研究设计

杰克逊心脏研究是一项基于社区的纵向队列研究。

研究地点与参与者

杰克逊心脏研究中自我报告的非裔美国人(n = 5306)。

暴露因素

G1和G2基因型以及镰状细胞性状。

研究结局

新发CKD(估计肾小球滤过率<60 mL/min/1.73 m²)、蛋白尿(尿白蛋白肌酐比值≥30 mg/g)、肾功能持续和快速下降(≥30%下降)以及新发ESKD。

分析方法

多变量线性和逻辑回归,以及经年龄、性别、高血压、糖尿病、祖先信息标记和镰状细胞性状调整的Cox比例风险模型。

结果

在2300名参与者中,41.3%有零个、45.1%有1个、13.6%有2个APOL1风险变异。8.5%存在镰状细胞性状。与零个APOL1风险变异的参与者相比,有2个等位基因的参与者在调整镰状细胞性状后发生蛋白尿(调整后风险比[aHR],1.88;95%可信区间[CI],1.04至3.40)、ESKD(aHR,9.05;95%CI,1.79至45.85)、新发CKD(aHR,1.65;95%CI,1.06至2.57)、持续下降(β = -1.90;95%CI,-3.35至-0.45)和肾功能快速下降(比值比,2.21;95%CI,1.22至4.00)的风险增加,调整祖先信息标记后结果相似。有1个APOL1风险变异与CKD结局无关,且APOL1与镰状细胞性状之间无相互作用。

局限性

对有APOL1和镰状细胞性状的非裔美国人进行单中心招募。

结论

存在1个APOL1风险等位基因与CKD结局风险增加无关,而2个风险等位基因与新发蛋白尿、CKD、ESKD以及肾功能快速和持续下降相关。需要进一步研究以确定可能改变高风险APOL1基因型个体不良肾脏结局风险的因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cca1/8664705/b3414d6d261d/fx1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验